Bristol-Myers Squibb Co. has completed its acquisition of Celgene Corp. following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, approval by Bristol-Myers Squibb and Celgene stockholders. It completed the acquisition Nov. 20.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
